Status:
COMPLETED
Novel Energy Metabolic Signaling Molecule With Therapeutic Potential
Lead Sponsor:
Petteri Hirvonen
Collaborating Sponsors:
University of Jyvaskyla
Conditions:
Healthy Participants
Eligibility:
All Genders
50-60 years
Phase:
EARLY_PHASE1
Brief Summary
Altogether a 25-day study. First 4 days non-blinded with water before 0-control blood samples (Day0). Thereafter blinded for 21 days (3 weeks). Study group was apparently healthy 50-60 -year-old males...
Detailed Description
Blinded 21-day period was divided into two sub-periods (7 days and 14 days) and it included 3 measurement days. All measurements were on the same day of each week to facilitate maximal comparability (...
Eligibility Criteria
Inclusion
- healthy 50-60 year-old females and males
Exclusion
- history of cardiovascular diseases, overweight (BMI \>32)
Key Trial Info
Start Date :
October 4 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT04713319
Start Date
October 4 2019
End Date
December 31 2021
Last Update
October 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Sports and Health Sciences, University of Jyväskylä
Jyväskylä, Central Finland, Finland, FI-40014